From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

naratuximab emtansine   Click here for help

GtoPdb Ligand ID: 9949

Synonyms: IMGN-529 | IMGN529 | K7153A-SMCC-DM1
Immunopharmacology Ligand
Compound class: Antibody
Comment: Naratuximab emtansine (IMGN529) is a CD37- targeting antibody drug conjugate carrying a potent anti-mitotic agent (maytansinoid DM1) payload. This ADC is being investigated for clinical efficacy as a treatment for B cell malignancies, with empahsis on diffuse large B cell lymphoma (DLBCL) in light of preliminary results from the phase 1 clinical trial NCT01534715 [4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, Mayo MF, Carrigan CN, Erickson HK, Pinkas J et al.. (2013)
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
Blood, 122 (20): 3500-10. [PMID:24002446]
2. EMA. 
EU/3/15/1494 naratuximab emtansine orphan designation.
Accessed on 11/05/2018. Modified on 11/05/2018. ema.europa.eu, http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2015/06/human_orphan_001581.jsp&mid=WC0b01ac058001d12b
3. FDA. 
Naratuximab emtansine orphan designation.
Accessed on 11/05/2018. Modified on 11/05/2018. fda.gov, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=518016
4. Stathis A, Flinn IW, Madan S, Maddocks K, Freedman A, Weitman S, Zucca E, Munteanu MC, Lia Palomba M. (2018)
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Invest New Drugs, 36 (5): 869-876. [PMID:29453628]